Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Recruiting · NCT05625633 · Registry updated 2024-04-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, common wart, human papilloma virus infection, infectious disease, sexually transmitted disease, skin disorder, skin disorder caused by infection, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 2 / Phase 3 | 2024-04-05 | NCT05625633 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| University of Utah | 319 |
| Western Institute for Veterans Research | 1 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Utah Midvalley Health Center | Salt Lake City | United States | 1 |
| VA Salt Lake City Health Care System | Salt Lake City | United States | 2 |